Hence, treating patients who have increased IL-6 levels with tocilizumab, an IL-6 receptor inhibitor, could be effective against severe MERS cases, and has also provided therapeutic advantages in treating COVID-19 (60, 61). This evidence concerns the gene IL6 and Middle East respiratory syndrome.